off my radar screen until they hit the top ten % losers group Friday------heres why
1. I never pay more than $10 for phase II results regardless of how compelling
2. To make my watch list a biotech firm has to meet three requirements
a. Deep pipeline
b. Strong management
c. Balance sheet strength sufficient to complete an NDA filing
3. You can ingore a. in the face of compelling Phase III results on a potential Blockbuster----never never ingore
b &c
4. ALXN fails 1,2a,and 2b
5. Their P&G deal seems to qualify them on 2c and their claim to fame thus far seems to be that Michael Murphy
is pumping them------and he has a strong following of deciples.
I Posted my short view on their Yahoo board----------told them to sell it and Buy GNTA------my #1 position right now
1. Genasense is a Blockbuster half way thru a pivatol Phase III trial for Melanoma-------holds fast-track and Orphan
status with FDA-------in multicenter trials for other indications-------will be an adjunct treatment for all forms
of Cancer which overexpress bcl-2---------$B market
2. Strongest management team of any biotech trading under 10 (closed at 8 1/2 fri)
3.Plenty of cash to finish trials with